Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19305264 | 0.76 | TSHR (0.40) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL19305261 | 0.76 | TSHR (0.40) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL23805159 | 0.76 | HCAR2 (0.43) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL6942354 | 0.74 | ALDH1A1 (0.43) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL6942352 | 0.74 | ALDH1A1 (0.43) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL4968872 | 0.74 | CA2 (0.43) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL13422202 | 0.73 | TDP1 (0.47) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL12257188 | 0.71 | HSP90AA1 (0.32) | HSP90AA1 | |
| SCHEMBL7196779 | 0.70 | HSP90AA1 (0.41) | HSP90AA1CA2CA4CA5AALOX15 | |
| SCHEMBL7153777 | 0.70 | TSHR (0.43) | HSP90AA1CA2CA4CA5AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344407-A1 | FENDILINE DERIVATIVES AND METHODS OF USE THEREOF | KRAS, RASSF5, RASSF2 | HSP90AA1 4468/4885CA2 3956/4885CA4 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.